Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid: A retrospective study of 109 consecutive patients

Scopsi, Lucio; Sampietro, Giuseppe; Boracchi, Patrizia; Bo, Romualdo Del; Gullo, Maria; Placucci, Marco; Pilotti, Silvana

doi:10.1002/(sici)1097-0142(19961115)78:10<2173::aid-cncr20>3.0.co;2-v

Cited by 94 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Survival at 10 years is 95% for patients with tumors limited to the thyroid, while it drops to 55%-70% in patients with persistent or recurrent disease. [1][2][3][4] Distant metastases are the main cause of death.…”

Section: Introductionmentioning

confidence: 99%

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Bodei

Handkiewicz-Junak

Grana

et al. 2004

Cancer Biotherapy and Radiopharmaceuticals

101

View full text Add to dashboard Cite

This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.

show abstract

Section: Introductionmentioning

confidence: 99%

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Bodei

Handkiewicz-Junak

Grana

et al. 2004

Cancer Biotherapy and Radiopharmaceuticals

101

View full text Add to dashboard Cite

show abstract

“…About 50±80% of non-screening patients have lymph node metastases at the time of diagnosis . At diagnosis, distant metastases have been reported to be present in about 5±15% (Dottorini et al 1996;Scopsi et al 1996). However, the high percentage of patients in whom calcitonin does not return to normal levels, despite extensive surgery, suggests that the real incidence of (occult) metastases beyond locoregional lymph nodes is much higher .…”

Section: Introductionmentioning

confidence: 99%

“…However, the high percentage of patients in whom calcitonin does not return to normal levels, despite extensive surgery, suggests that the real incidence of (occult) metastases beyond locoregional lymph nodes is much higher . A 10-year survival rate of 55±70% has been reported (Bergholm et al 1997;Dottorini et al 1996;Scopsi et al 1996). Hence, the prognosis of MTC is worse than dierentiated thyroid carcinoma but better than undierentiated thyroid carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma

Gimm

Sutter²,

Dralle³

2001

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy. About 75% are sporadic (sMTC) while the remaining 25% are hereditary (hMTC). The treatment of choice for both sMTC and hMTC is surgery. An adequate initial operation provides the best chance of cure. Hence, the diagnosis of MTC should be made preoperatively. In sMTC, ultrasound, ultrasound-guided fine-needle aspiration cytology and measurement of calcitonin levels (basal and after injection of calcitonin-stimulating reagents, e.g., pentagastrin) are sensitive diagnostic tools. In hMTC, identification of a germline mutation in the proto-oncogene RET is sufficient for making the diagnosis. Total thyroidectomy is recommended in all patients, sporadic and hereditary. In addition, lymphadenectomy of the cervicocentral and both cervicolateral compartments should be performed. The only indication to perform a less extensive operation may be given in young patients with hMTC. Sufficient treatment of MTC beyond local disease is still non-existent. Future research should concentrate on this issue.

show abstract

“…Scopsi and coworkers 59 have analyzed the prognosis of a group of 109 patients with sporadic MTC. The series included 57 males and 52 females, with mean ages of 45 years and 48 years, respectively.…”

Section: Prognosismentioning

confidence: 99%

Medullary Thyroid Carcinoma

DeLellis¹

2006

Pathology Case Reviews

View full text Add to dashboard Cite

Medullary thyroid carcinomas (MTCs) are currently defined as malignant tumors with evidence of C-cell differentiation. They comprise 5%-10% of all thyroid malignancies and occur sporadically (75%) or as a manifestation of the type 2 multiple endocrine neoplasia syndromes (25%). Results of calcitonin screening in patients with nodules thyroid disease have revealed a mean prevalence of tumors of 0.61% (range, 0.24% to 2.85%), most of which represent microscopic or incidental MTCs measuring less than 1 cm. While heritable and sporadic tumors contain amyloid and have a lobular to solid growth pattern and polyhedral-to spindleshaped cells, numerous variants of these tumors also occur. C-cell hyperplasia (CCH) has been regarded as the precursor of heritable MTCs, although recent studies suggest that CCH is a clonal process and should be considered a form of intraepithelial C-cell neoplasia. Activating germline mutations of RET, primarily affecting exons 10 and 11, with less frequent involvement of exons 13, 14, 15, and 16, represent the molecular basis for the development of heritable MTCs. Somatic RET mutations, primarily affecting codon 918, occur in a substantial proportion of sporadic MTCs. Five-year and 10-year survivals for sporadic MTCs are 65% and 50%, respectively, with major risk factors for unfavorable outcome including tumor stage, male sex, and age greater than 60 years. With the development of molecular testing for RET mutations, the prognosis for patients with heritable MTCs is generally excellent.

show abstract

Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid: A retrospective study of 109 consecutive patients

Cited by 94 publications

References 26 publications

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma

Medullary Thyroid Carcinoma

Contact Info

Product

Resources

About

Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid: A retrospective study of 109 consecutive patients

Cited by 94 publications

References 26 publications

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma

Medullary Thyroid Carcinoma

Contact Info

Product

Resources

About

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas